The recent failure of the high-profile Phase 3 LAGOON trial involving Zepzelca has sent shockwaves through the oncology community, raising urgent questions about the reliability of surrogate endpoints in modern drug regulation. While the drug initially received accelerated approval based on a
The delicate balance between providing high-quality patient care and maintaining the fiscal health of a medical institution is frequently disrupted by the sudden impact of legal non-compliance. Healthcare administrators who lack a robust understanding of the statutes governing their industry often
The historical paradigm where Western laboratories exclusively dictated the rhythm of pharmaceutical progress is rapidly disintegrating as China establishes itself as a primary source of high-value drug candidates. For many decades, the global healthcare sector followed a remarkably predictable
The emergence of chimeric antigen receptor T-cell therapy has revolutionized the oncological landscape by providing a potent "living drug" that can hunt and destroy malignant cells, yet nearly half of all patients still experience clinical relapses that threaten the long-term viability of this
Ivan Kairatov joins us today to share his deep expertise in biopharmaceutical innovation, particularly within the specialized field of rare kidney diseases. With a career rooted in the research and development of transformative therapies, Kairatov offers a unique perspective on the shifting
The journey of a life-saving injectable molecule often begins with a deceptive sense of simplicity on a laboratory bench, only to face an unforgiving reality when moved toward large-scale clinical manufacturing. While the ambition to reach in-human trials quickly is a common driver for drug owners,
